Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a stock price increase of over 5%, currently trading at HKD 3.79, with a transaction volume of HKD 6.119 million, following the announcement of FDA approval for its eye drop product [1] Group 1: FDA Approval and Product Details - Zhaoke Ophthalmology announced that its partner, Tenpoint Therapeutics, has received FDA approval for the commercialization of Carbachol and Bromonidine Tartrate Eye Drops (2.75%/0.1%) [1] - The eye drop, known as BRIMOCHOL PF during clinical trials, will be marketed in the U.S. under the name YUVEZZI, aimed at treating presbyopia [1] Group 2: Commercial Strategy and Partnerships - The FDA approval is considered a strong catalyst for Zhaoke Ophthalmology as it formulates its commercialization strategy [1] - The company has established a partnership network for BRIMOCHOL PF, which currently includes eight commercial partners across the Asia-Pacific region (including South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan/Hong Kong/Macau, Singapore, and Vietnam) and the Middle East [1] - With FDA recognition, Zhaoke anticipates accelerating the market launch of the drug, marking a significant global milestone [1]

Core Viewpoint - Tenpoint Therapeutics, Ltd. has received FDA approval for the commercialization of BRIMOCHOL PF, an innovative eye drop treatment for presbyopia, which will be marketed as YUVEZZI in the U.S. [1] Group 1 - The approval follows the successful completion of Phase 3 clinical trials, with the first key Phase 3 study (BRIO I) demonstrating the combination therapy's superiority over individual therapies [1] - The second Phase 3 study (BRIO II) achieved all primary endpoints for near vision improvement, showing a statistically significant increase in binocular uncorrected near visual acuity (BUCNVA) by three lines or more, while binocular uncorrected distance visual acuity (BUCDVA) did not decrease by one line or more [1] Group 2 - During the BRIO II study, BRIMOCHOL PF showed good tolerability with no serious treatment-related adverse events reported, and the incidence of eye redness was low [2] - The report rate of eye redness for subjects receiving BRIMOCHOL PF was 2.8%, significantly lower than the 10.7% for those receiving only carbachol [2] Group 3 - This FDA approval serves as a strong catalyst for the company's commercialization strategy, with a partnership network established across the Asia-Pacific region and the Middle East, including eight commercial partners [2] - With FDA recognition, the company anticipates accelerating the market entry of BRIMOCHOL PF, marking an important global milestone [2]

Core Insights - Tenpoint Therapeutics, Ltd. has received FDA approval for the commercialization of BRIMOCHOL PF (2.75%/0.1%), an innovative eye drop for the treatment of presbyopia, which will be marketed as YUVEZZI in the U.S. [1][2] Group 1: Clinical Trial Results - The approval follows the successful completion of Phase 3 clinical trials, with the first key Phase 3 study (BRIO I) demonstrating that the combination therapy is more effective than individual active drug compounds [1] - In the second placebo-controlled Phase 3 study (BRIO II), BRIMOCHOL PF met all primary endpoints for near vision improvement, showing a statistically significant increase in binocular uncorrected near visual acuity (BUCNVA) by three lines or more, while binocular uncorrected distance visual acuity (BUCDVA) did not decrease by one line or more [1] Group 2: Safety and Tolerability - During the monitoring of over 72,000 treatment days in the BRIO II study, BRIMOCHOL PF was well-tolerated, with no treatment-related serious adverse events observed [2] - The incidence of eye redness (conjunctival hyperemia) as a reported adverse event was low, with a rate of 2.8% in BRIMOCHOL PF recipients compared to 10.7% in those receiving only carbachol [2] Group 3: Commercial Strategy - The FDA approval serves as a strong catalyst for the company's commercialization strategy, as it has established a partnership network for BRIMOCHOL PF, including eight commercial partners across the Asia-Pacific region and the Middle East [2] - With FDA recognition, the company anticipates accelerating the market entry of the drug, marking a significant global milestone [2]

消息面上，1月26日，兆科眼科宣布，将其核心老花眼治疗药物BRIMOCHOL PF在新加坡和越南的独家 商业化权利，分别授予新西兰的AFT Pharmaceuticals和日本的千寿制药。至此，兆科眼科其全球化商业 版图已延伸至韩国、澳洲、新西兰、泰国、印度尼西亚、台湾地区、新加坡和越南八个市场。 兆科眼科-B(06622)盘中涨超7%，截至发稿，涨3.44%，报3.61港元，成交额1143.15万港元。 根据协议，兆科眼科授予AFT在新加坡、授予千寿在越南的独家分销权。AFT Pharmaceuticals 是一家总 部位于新西兰的跨国制药公司，其商业模式核心在于在全球超过125个国家开发和授权产品。千寿制药 则是一家以研发为核心的日本私人制药公司，尤其在眼科领域深耕多年，旨在通过原创药品提升全球患 者的视力健康。 ...

Core Viewpoint - The stock of Zhaoke Ophthalmology-B (06622) has increased by over 5%, reflecting positive market sentiment following the expansion of its partnership agreement with AFT Pharmaceuticals Limited for the commercialization of BRIMOCHOL PF in Singapore [1] Group 1: Partnership Expansion - Zhaoke Ophthalmology-B has expanded its partnership with AFT Pharmaceuticals to commercialize BRIMOCHOL PF in Singapore [1] - The company has also established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize the product in Vietnam [1] - AFT and Santen are now the seventh and eighth commercialization partners for BRIMOCHOL PF, indicating the company's commitment to global expansion [1] Group 2: Product Information - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia [1] - The product is a core asset acquired through a licensing agreement with Tenpoint Therapeutics, Ltd. [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a stock price increase of over 5%, currently trading at 3.44 HKD with a transaction volume of 1.707 million HKD, following the announcement of expanded partnerships for the commercialization of BRIMOCHOL PF in Singapore and Vietnam [1] Group 1: Partnerships and Agreements - The company has expanded its partnership agreement with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL PF in Singapore [1] - Zhaoke has established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize the product in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights for BRIMOCHOL PF in their respective markets, which includes rights for registration, import, promotion, distribution, marketing, and sales [1] Group 2: Product Information - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia, representing a core asset acquired through a partnership with Tenpoint Therapeutics, Ltd. [1] - The addition of AFT and Santen as commercialization partners marks the seventh and eighth partners for BRIMOCHOL PF, highlighting the company's commitment to global expansion [1]

Market Overview - The Hong Kong stock index opened slightly higher on January 27, with the Hang Seng Index rising by 0.36% to 26,863.15 points, the Hang Seng Tech Index increasing by 0.16% to 5,734.9 points, and the National Enterprises Index up by 0.28% to 9,173.2 points [1] - Major tech stocks mostly rose, with Alibaba up by 0.97%, Tencent Holdings up by 0.08%, and JD.com down by 0.17% [1] - Automotive stocks were active, with BYD rising by over 1%, while gold stocks saw some increases, with Zijin Mining up by over 4% [1] Company News - China Power (02380.HK) reported a total consolidated electricity sales volume of 10.73105 million MWh for December 2025, a decrease of 2.31% year-on-year, with an annual cumulative total of approximately 126 million MWh, down by 1.27% year-on-year [2] - Harbin Electric (01133.HK) expects a net profit attributable to shareholders of approximately RMB 2.65 billion for the fiscal year 2025, compared to RMB 1.686 billion in the previous year [2] - Singularity National Peak (01280.HK) has entered into a GPU distribution cooperation agreement with Muxi Co., aiming to enter the domestic AI computing power market [3] - East Sunshine Pharmaceutical (06887.HK) has signed a strategic cooperation agreement with Shenzhen Jingtai to establish a joint venture for an AI-driven drug research and development platform [4] - Weisheng Pharmaceutical-B (02561.HK) has received approval from the National Medical Products Administration for the marketing authorization application of injectable Long Pei growth hormone [5] - Kexin Pharmaceutical-B (02171.HK) issued a profit warning, expecting a net loss for 2025 to be reduced to no more than approximately RMB 120 million [6] - Zhenghong Pharmaceutical (01276.HK) has received a clinical trial approval notice for SHR-1049 injection [7] - Baolong Real Estate (01238.HK) has had its bond restructuring plan approved by the relevant bondholders' meeting [8] - Aobo Technology Holdings (08279.HK) has entered into a technical service agreement with Hong Kong Gold Trading Co., Ltd. [9] - Future Data Group (08229.HK) has signed a strategic cooperation framework agreement with Linghe Culture [10] - Haowei Group (00501.HK) plans to invest up to USD 50 million to subscribe for shares in Aixin Yuan Zhi's initial public offering [11] Institutional Insights - Huatai Securities noted that foreign and southbound capital continues to flow in, with public fund positions in Hong Kong stocks dropping to 23% in Q4, significantly reducing potential selling pressure [12] - Goldman Sachs has raised its year-end gold price forecast from USD 4,900 to USD 5,400 per ounce due to increasing demand from private investors and central banks [12] - CITIC Securities recommends focusing on cloud computing service providers and continuing to recommend AI computing power sectors and AI applications, highlighting the ongoing AI industrial revolution [12]

Group 1 - The company has expanded its partnership with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL PF in Singapore [1] - A strategic partnership has been established with Santen Pharmaceutical Co., Ltd. to commercialize the product in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights for BRIMOCHOL PF in their respective markets, highlighting the company's commitment to global expansion [1] Group 2 - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia, acquired through a partnership with Tenpoint Therapeutics, Ltd. [2] - Tenpoint is a global biotechnology company developing breakthrough therapies to restore vision in aging eyes [2] - The FDA has accepted the new drug application for BRIMOCHOL PF, with a review deadline set for January 28, 2026 [2]

Group 1 - The company has expanded its partnership agreement with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL PF in Singapore [1] - The company has established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize BRIMOCHOL PF in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights for BRIMOCHOL PF in their respective markets, marking them as the seventh and eighth commercialization partners for the product [1] Group 2 - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia, acquired as a core asset through a partnership with Tenpoint Therapeutics, Ltd. [2] - Tenpoint is a global biotechnology company developing breakthrough therapies to restore vision in aging eyes [2] - The FDA has accepted the new drug application for BRIMOCHOL PF, with a review deadline set for January 28, 2026 [2]

Group 1 - The core viewpoint of the article is that Zhaoke Ophthalmology-B (06622) has entered into a strategic partnership with Dongshenghua Pharmaceutical to jointly advance the clinical introduction and future commercialization of BRIMOCHOL PF in Taiwan [1] - Under the agreement, Zhaoke grants Dongshenghua exclusive distributor rights for the registration, importation, promotion, distribution, marketing, and sales of BRIMOCHOL PF in Taiwan [1] - The developer of BRIMOCHOL PF, Tenpoint Therapeutics, Ltd., announced that the FDA has accepted the new drug application for the product, with a review deadline set for January 28, 2026, under the Prescription Drug User Fee Act (PDUFA) [1]